Monthly News Roundup - September 2017

FDA Approves Lilly ’s Verzenio: Targeted Breast Cancer Treatment Lilly’s Verzenio (abemaciclib), a CDK 4/6 inhibitor breast cancer treatment, has been FDA-approved. Verzenio is used in 2 patient populations: either with fulvestrant (Faslodex)...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news